Cannabinoid Encyclopedia

Cannabinoid guide

What is CBGV?

A clear guide to CBGV: what it is, what researchers have studied, how strong the evidence is, and what to know about safety.

Updated July 2026 12 research sources Mostly early-stage research

The short answer

CBGV, in simple terms

CBGV is a cannabinoid-related compound represented in the scientific literature. Researchers study it for possible effects, safety, and how it works in the body. Most of the current evidence is preclinical or focused on biological mechanisms. The evidence does not turn this into one proven benefit, because studies can use different products, doses, routes, people, and outcomes. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBGV.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into CBGV

What CBGV is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Too limited for a firm answer

    Rare phytocannabinoids

    Researchers have examined CBGV in connection with Rare phytocannabinoids. The source details determine whether that is a human finding, an early model, or an open question. 1

    See research areas

  2. Mostly mechanism-focused

    Receptor, target, metabolic, and pharmacology mechanisms

    Researchers have looked at CBGV in appetite or metabolism-related models. That does not show that it changes appetite, weight, or metabolism for people. 2

    See research areas

  3. Mostly mechanism-focused

    Pain-related outcomes

    People look at CBGV for pain because the literature includes pain models, sensory signaling, or related pharmacology. That does not establish pain relief in people. 3

    See research areas

  4. Too limited for a firm answer

    Receptors and pharmacology

    This is part of the biological explanation for why CBGV may have effects in cells or models. Mechanism research does not by itself show a health benefit in people. 4

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    Research on CBGV covers Rare phytocannabinoids, Receptor, target, metabolic, and pharmacology mechanisms, and Pain-related outcomes; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What has CBGV been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Rare phytocannabinoids

Researchers have examined CBGV in connection with Rare phytocannabinoids. The studies may differ in compound, formulation, dose, route, population, and outcome. 1

Mostly mechanism-focused

Receptor, target, metabolic, and pharmacology mechanisms

Studies connect CBGV with Receptor, target, metabolic, and pharmacology mechanisms at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 2

Mostly mechanism-focused

Pain-related outcomes

Researchers have examined CBGV in connection with Pain-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 3

Too limited for a firm answer

Receptors and pharmacology

Researchers have examined CBGV in connection with Receptors and pharmacology. The studies may differ in compound, formulation, dose, route, population, and outcome. 4

Too limited for a firm answer

Safety, risk, adverse events, and formulation concerns

Researchers have examined CBGV in connection with Safety, risk, adverse events, and formulation concerns. The studies may differ in compound, formulation, dose, route, population, and outcome. 5

Mostly mechanism-focused

Skin and inflammatory dermatology

Researchers have examined CBGV in connection with Skin and inflammatory dermatology. The studies may differ in compound, formulation, dose, route, population, and outcome. 6

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

2 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

1 source

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

3 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 6 of 12 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBGV is not one kind of study. This source set includes 3 animal studies, 2 cell or laboratory studies, and 1 narrative or expert review. 3

The recorded populations or models include animal models (2 sources), people or patients (2 sources), and cells or tissue models (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is rare phytocannabinoids research topics (7 sources), receptor, target, metabolic, or pharmacology mechanisms (2 sources), and pain-related outcomes (1 source). Closely related outcome names can still describe different measurements. 5

The CBGV source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa.

On this page, this source examines THC and rare phytocannabinoids research topics. 1

Study type
narrative or expert review
Outcome focus
rare phytocannabinoids research topics
Evidence stage
evidence still limited

animal study

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

On this page, this source examines THC activity involving TRP channel activity or ionotropic cannabinoid target mechanisms, THCV activity involving receptor, target, metabolic, or pharmacology mechanisms, and THC activity involving TRPM8. 2

Study type
animal study
Population or model
people or patients
Outcome focus
tRP channel activity or ionotropic cannabinoid target mechanisms and receptor, target, metabolic, or pharmacology mechanisms and other recorded details
Evidence stage
mechanism-focused research

animal study

Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain.

On this page, this source examines CBC and pain-related outcomes. 3

Study type
animal study
Population or model
animal models
Outcome focus
pain-related outcomes
Evidence stage
mechanism-focused research

evidence still limited

Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.

On this page, this source examines THC and receptor, target, or pharmacology mechanisms. 4

Outcome focus
receptor, target, or pharmacology mechanisms
Evidence stage
evidence still limited

evidence still limited

A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.

On this page, this source examines THC and rare phytocannabinoids research topics and THC and safety, risk, adverse-event, or formulation-specific concerns. 5

Population or model
pediatric, adolescent, or developmental context
Outcome focus
rare phytocannabinoids research topics and safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CBGV should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 5

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is CBGV?

CBGV is a cannabinoid-related compound studied across Rare phytocannabinoids, Receptor, target, metabolic, and pharmacology mechanisms, Pain-related outcomes, and Receptors and pharmacology. This page separates those research questions so they are not mistaken for one broad claim. 7

What has CBGV been studied for?

The current source set includes Rare phytocannabinoids, Receptor, target, metabolic, and pharmacology mechanisms, Pain-related outcomes, and Receptors and pharmacology. Each area may use different doses, products, routes, populations, and outcome measures. 8

How strong is the research on CBGV?

Most of the current evidence is preclinical or focused on biological mechanisms. 9

Is CBGV safe?

Safety cannot be answered for CBGV without context. Dose, route, formulation, medications, and the person using it can all change risk. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. narrative or expert review; evidence still limited PubMed 35648593 DOI 10.1021/acs.jnatprod.2c00155
  2. 2
    Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. animal study; mechanism-focused research PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
  3. 3
    Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain. animal study; mechanism-focused research PubMed 36551296 DOI 10.3390/biom12121869
  4. 4
    Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures. evidence still limited PubMed 35566314 DOI 10.3390/molecules27092965
  5. 5
    A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. evidence still limited PubMed 38940871 DOI 10.1007/s00216-024-05396-5
  6. 6
    Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. cell or laboratory study; mechanism-focused research PubMed 27094344 DOI 10.1111/exd.13042
  7. 7
    Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. animal study; mechanism-focused research PubMed 21726418 DOI 10.1111/j.1748-1716.2011.02338.x
  8. 8
    Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. evidence still limited PubMed 34617621 DOI 10.1002/mrc.5224
  9. 9
    Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. evidence still limited PubMed 34078070 DOI 10.1021/acs.joc.1c00451
  10. 10
    Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. cell or laboratory study; evidence still limited PubMed 38885660 DOI 10.1055/a-2320-8822
  11. 11
    Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. evidence still limited PubMed 36770831 DOI 10.3390/molecules28031164
  12. 12
    Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products. evidence still limited PubMed 36827690 DOI 10.1021/acs.jnatprod.2c01008
See all 12 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran. evidence still limited / 1 linked research note PubMed 34617621
  2. Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products. evidence still limited / 1 linked research note PubMed 36827690
  3. Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38885660
  4. Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa. narrative or expert review; evidence still limited / 1 linked research note PubMed 35648593
  5. Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases. evidence still limited / 1 linked research note PubMed 36770831
  6. Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. evidence still limited / 1 linked research note PubMed 34078070
  7. A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. evidence still limited / 2 linked research notes PubMed 38940871
  8. Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures. evidence still limited / 1 linked research note PubMed 35566314
  9. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. animal study; mechanism-focused research / 3 linked research notes PubMed 21175579
  10. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 27094344
  11. Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain. animal study; mechanism-focused research / 1 linked research note PubMed 36551296
  12. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. animal study; mechanism-focused research / 3 linked research notes PubMed 21726418